Cancer Research Annual Meeting 2010  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Verra, N. C. V.
Right arrow Articles by Luiten, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Verra, N. C. V.
Right arrow Articles by Luiten, R. M.
[Cancer Research 64, 2153-2161, March 15, 2004]
© 2004 American Association for Cancer Research


Immunology

Human Telomerase Reverse Transcriptase-Transduced Human Cytotoxic T Cells Suppress the Growth of Human Melanoma in Immunodeficient Mice

Natascha C. V. Verra, Annelies Jorritsma, Kees Weijer, Janneke J. Ruizendaal, Arie Voordouw, Pauline Weder, Erik Hooijberg, Ton N. M. Schumacher, John B. A. G. Haanen, Hergen Spits and Rosalie M. Luiten

Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Immunotherapy of melanoma by adoptive transfer of tumor-reactive T lymphocytes aims at increasing the number of activated effectors at the tumor site that can mediate tumor regression. The limited life span of human T lymphocytes, however, hampers obtaining sufficient cells for adoptive transfer therapy. We have shown previously that the life span of human T cells can be greatly extended by transduction with the human telomerase reverse transcriptase (hTERT) gene, without altering antigen specificity or effector function. We developed a murine model to evaluate the efficacy of hTERT-transduced human CTLs with antitumor reactivity to eradicate autologous tumor cells in vivo. We transplanted the human melanoma cell line melAKR or melAKR-Flu, transduced with a retrovirus encoding the influenza virus/HLA-A2 epitope, in RAG-2-/- IL-2R{gamma} -/- double knockout mice. Adoptive transfer of the hTERT-transduced influenza virus-specific CTL clone INFA24 or clone INFA13 inhibited the growth of melAKR-Flu tumors in vivo and not of the parental melAKR melanoma cells. Furthermore, the hTERT-transduced CTL clone INFA13 inhibited tumor growth to the same extent in vivo as the untransduced CTL clone, as determined by in vivo imaging of luciferase gene-transduced melAKR-Flu tumors, indicating that hTERT did not affect the in vivo function of CTL. These results demonstrate that hTERT-transduced human CTLs are capable of mediating antitumor activity in vivo in an antigen-specific manner. hTERT-transduced MART-1-specific CTL clones AKR4D8 and AKR103 inhibited the growth of syngeneic melAKR tumors in vivo. Strikingly, melAKR-Flu cells were equally killed by the MART-1-specific CTL clones and influenza virus-specific CTL clones in vitro, but only influenza-specific CTLs were able to mediate tumor regression in vivo. The influenza-specific CTL clones were found to produce higher levels of IFN{gamma} on tumor cell recognition than the MART-1-specific CTL clones, which may result from the higher functional avidity of the influenza virus-specific CTL clones. Also, melAKR-Flu tumors were growing faster than melAKR tumors, which may have surpassed the relatively modest antitumor effect of the MART-1-specific CTL, as compared with the influenza virus-specific CTL. Taken together, the adoptive transfer model described here shows that hTERT-transduced T cells are functional in vivo, and allows us to evaluate the balance between functional activity of the CTL and tumor growth rate in vivo, which determines the efficacy of CTLs to eradicate tumors in adoptive transfer therapy.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
I. Verbrugge, E. H.J. Wissink, R. W. Rooswinkel, J. Jongsma, N. Beltraminelli, M. Dupuis, J. Borst, and M. Verheij
Combining Radiotherapy with APO010 in Cancer Treatment
Clin. Cancer Res., March 15, 2009; 15(6): 2031 - 2038.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. Marttila-Ichihara, R. Turja, M. Miiluniemi, M. Karikoski, M. Maksimow, J. Niemela, L. Martinez-Pomares, M. Salmi, and S. Jalkanen
Macrophage mannose receptor on lymphatics controls cell trafficking
Blood, July 1, 2008; 112(1): 64 - 72.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. S. Singhal, Y. C. Awasthi, and S. Awasthi
Regression of Melanoma in a Murine Model by RLIP76 Depletion
Cancer Res., February 15, 2006; 66(4): 2354 - 2360.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. W. J. Schreurs, M. A. J. A. Hermsen, R. I. K. Geltink, K. B. J. Scholten, A. A. T. P. Brink, E. W. M. Kueter, M. Tijssen, C. J. L. M. Meijer, B. Ylstra, G. A. Meijer, et al.
Genomic stability and functional activity may be lost in telomerase-transduced human CD8+ T lymphocytes
Blood, October 15, 2005; 106(8): 2663 - 2670.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.